🍽 Caloric Restriction Mimetic Drug Discovery Pipeline Simulator

Why Mimic Caloric Restriction

Caloric restriction extends lifespan in many species; mimetics aim to copy that effect pharmacologically.

• ~30%: CR lifespan extension (in model organisms)
• 3: Key pathways (AMPK, mTOR, sirtuins)
• ~5: Known mimetic classes (e.g. metformin, rapamycin)
• dozens: Human trials ongoing (placeholder estimate)

The core hypothesis

CR mimetics target the same nutrient-sensing pathways activated by restriction.

Why not just restrict calories

Sustained restriction is impractical for most people, motivating a drug alternative.

Placeholder: mimetics could deliver benefits without dietary restriction.

High-Throughput Screening for Hits

Large compound libraries are screened against CR-pathway biomarkers to find candidate hits.

• 10⁴–10⁶: Compounds screened (typical library size)
• ~0.1–1%: Hit rate (placeholder estimate)
• multi: Assay readouts (AMPK/mTOR/sirtuin activity)
• 2–3: Screening rounds (primary + confirmatory)

Assay design

Placeholder: reporter assays flag compounds that activate CR-linked pathways.

Filtering false positives

Placeholder: counter-screens remove non-specific and toxic hits.

Placeholder: most hits fail confirmatory screening.

Validating Hits in Living Systems

Surviving hits are tested in yeast, worms, and mice to confirm lifespan and healthspan effects.

• 3: Model organisms used (yeast, C. elegans, mouse)
• high: Validation attrition (placeholder estimate)
• months–years: Typical study length (depends on organism)
• multi: Endpoints tracked (lifespan, biomarkers)

Cross-species confirmation

Placeholder: effects must replicate across multiple model organisms.

Dose and safety checks

Placeholder: toxicity and dose-response are characterized early.

Placeholder: cross-species consistency raises translational confidence.

Refining the Lead Compound

Medicinal chemistry improves potency, selectivity, and pharmacokinetics of surviving leads.

• hundreds: Analogs synthesized (placeholder estimate)
• several: Optimization cycles (iterative rounds)
• multi: Key properties tuned (potency, half-life, safety)
• 1–3: Leads remaining (placeholder estimate)

Structure-activity refinement

Placeholder: iterative chemistry improves target engagement.

Pharmacokinetic tuning

Placeholder: absorption and stability are optimized for dosing.

Placeholder: optimization narrows the field to few final leads.

Toward Human Clinical Testing

The optimized lead advances through regulatory and clinical trial phases toward approval.

• 3: Trial phases (Phase I, II, III)
• ~10yr: Preclinical to approval (placeholder estimate)
• low: Overall success rate (placeholder estimate)
• multi: Regulatory bodies (e.g. FDA, EMA)

Regulatory filing

Placeholder: preclinical data package supports an IND-style filing.

Trial phases

Placeholder: safety, efficacy, and scale are tested in sequence.

Placeholder: most candidates do not reach approval.